Radioactive antibody targets Hard-to-Treat cancers
NCT ID NCT03746431
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This early-phase study tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours (like breast, ovarian, or head and neck cancers) that had stopped responding to standard treatments. The drug uses a radioactive particle attached to an antibody that targets a protein found on many cancer cells. The trial was terminated early, so we have limited information on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
Centre Hospitalier De I'Universite de Montreal
Montreal, Quebec, H2X 0C1, Canada
-
City of Hope
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Juravinski Cancer Center - Hamilton Health
Hamilton, Ontario, L8V 5C2, Canada
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
Quebec University Hospital- Laval
Québec, Quebec, G1R 2J6, Canada
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radioactive antibody (225Ac-FPI-1434) that targets cancer cells
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumours that have not responded to other therapies.
What could go wrong
This was a very early (phase 1) trial that was terminated, so results are limited. The treatment involves radiation, which can cause side effects, and it is unclear if it will be effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.